NASDAQ · ICUCW
Healthcare · Biotechnology
$0.02
Up+$0.00 (+0.00%)
Updated Aug 25, 2026, 4:12 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 16 trading sessions · Daily adjusted prices
ICUCW closed at $0.02 after 16 trading sessions, down 4.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | $0.0174 | $0.0191 | $0.0173 | $0.0191 | 8.69K |
| Aug 20, 2026 | $0.0201 | $0.0201 | $0.0175 | $0.0196 | 20.01K |
| Aug 19, 2026 | $0.0247 | $0.0247 | $0.0196 | $0.021 | 21.98K |
| Aug 17, 2026 | $0.0197 | $0.0225 | $0.0197 | $0.0224 | 320 |
| Aug 14, 2026 | $0.0202 | $0.0249 | $0.0201 | $0.0202 | 1.8K |
| Aug 13, 2026 | $0.025 | $0.025 | $0.0199 | $0.0225 | 400 |
| Aug 12, 2026 | $0.0197 | $0.0199 | $0.0197 | $0.0199 | 19.8K |
| Aug 11, 2026 | $0.0197 | $0.0197 | $0.0197 | $0.0197 | 101 |
| Aug 10, 2026 | $0.0197 | $0.0197 | $0.019 | $0.019 | 1.83K |
| Aug 6, 2026 | $0.0188 | $0.0199 | $0.0168 | $0.0198 | 25.59K |
| Aug 5, 2026 | $0.0188 | $0.02 | $0.0188 | $0.02 | 5.93K |
| Aug 4, 2026 | $0.0199 | $0.0203 | $0.0199 | $0.0199 | 23.7K |
| Aug 3, 2026 | $0.0193 | $0.02 | $0.019 | $0.0199 | 2.55K |
| Jul 31, 2026 | $0.0193 | $0.0193 | $0.0193 | $0.0193 | 158 |
| Jul 30, 2026 | $0.0199 | $0.0199 | $0.0193 | $0.0193 | 3.64K |
| Jul 29, 2026 | $0.019 | $0.02 | $0.019 | $0.02 | 11.23K |
The latest Smart Investors Daily articles mentioning ICUCW.
ICUCW research
Company profile and research snapshot.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Aug 13, 2026
Pediatric adoption doubles to 20 top children's hospitals, while Neutralize-AKI trial enrollment accelerates toward late-2027 PMA submission.
Yahoo · Aug 13, 2026
Revenue surged 82% year-over-year as hospital adoption doubled to 20 sites.
Yahoo · Aug 12, 2026
Added 3 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI Obtained ICD-10-PCS codes to enable standardized inpatient hospital billing for its selective cytopheretic device (SCD) therapy, including QUELIMMUNE Webcast today at 4:30 pm Eastern Time DENVER, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Hol
SeekingAlpha · Aug 12, 2026
SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsEric Schlorff - CEO, Treasurer, President...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ICUCW.
No results
No recent SID articles mention ICUCW.
